

<p align="center">EMENDAMENTO Numero 1 (di seguito “Emendamento”) è efficace a partire dalla data dell'ultima firma (di seguito “Data di entrata in vigore”)</p>	<p align="center">AMENDMENT Number 1 (hereinafter “Amendment”) is effective as of the date of last signature (hereinafter “Effective date”)</p>
<p align="center">al CONTRATTO PER LA CONDUZIONE DELLA SPERIMENTAZIONE CLINICA SU MEDICINALI (di seguito “Accordo”) del 17.9.2024</p>	<p align="center">to the AGREEMENT FOR THE CONDUCT OF A CLINICAL TRIAL ON MEDICINAL PRODUCTS (hereinafter “Agreement”) dated 17.9.2024</p>
<p align="center">Il presente Emendamento è stipulato da e tra</p>	<p align="center">This Amendment is made by and between</p>
<p align="center">Mirati Therapeutics, Inc., Route 206 and Province Line Road, Princeton, New Jersey, 08543, USA (hereinafter “SPONSOR”)</p>	<p align="center">Mirati Therapeutics, Inc., Route 206 and Province Line Road, Princeton, New Jersey, 08543, USA (hereinafter “SPONSOR”)</p>
<p align="center">e</p>	<p align="center">and</p>
<p>l’Azienda Sanitaria Territoriale di Pesaro e Urbino (di seguito “AST PU” oppure “Ente”), con sede legale in Piazzale Cinelli n. 4, 61121 PESARO (PU) – Italia, C.F. e P. IVA n. 02789340417, in persona del legale rappresentante, Dott. Alberto Carelli, in qualità di Direttore Generale che agisce in nome e per conto dell’AST PU e che per la sottoscrizione del presente atto ha delegato (con nota prot. n. 28071 del 09.05.2024) il Dott. Matteo Biraschi, Direttore Amministrativo dell’AST PU</p>	<p>Azienda Sanitaria Territoriale di Pesaro e Urbino (hereinafter “AST PU” or “Institution”), with registered office at Piazzale Cinelli n. 4, 61121 PESARO (PU) – Italy, Tax Code and VAT No. 02789340417, represented by its legal representative, Dr. Alberto Carelli, General Director who acts in the name and on behalf of AST PU and who has delegated Dr. Matteo Biraschi, Administrative Director of AST PU for the signing of this deed (with note protocol. number 28071 dated May 9, 2024)</p>
<p align="center">riguardo a</p>	<p align="center">regarding</p>
<p>Protocollo: 849-021/CA239-0012 (di seguito Protocollo) "Studio randomizzato su due dosaggi di adagrasib in pazienti con carcinoma polmonare non a piccole cellule con mutazione KRAS G12C già trattato in precedenza " (di seguito "Sperimentazione") Adagrasib (BMS-986503) e (in seguito “Medicinali Sperimentali”)</p>	<p>Protocol No: 849-021/CA239-0012 (hereinafter “Protocol”) A Randomized Study of Two Dosing Regimens of Adagrasib in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (hereinafter “Study”) Adagrasib (BMS-986503) (hereinafter “Study Drug”)</p>
<p>SPONSOR, Ente e Sperimentatore sono di seguito indicati singolarmente come “Parte” e collettivamente come “Parti”.</p>	<p>SPONSOR, Institution and Investigator are hereinafter referred to individually as a “Party” and collectively as the “Parties”.</p>
<p>Premesso che lo SPONSOR è lo sponsor dello Studio multicentrico per la valutazione clinica del Farmaco in Studio;</p>	<p>WHEREAS, SPONSOR is the sponsor of the multi-center Study to clinically evaluate the Study Drug;</p>
<p>PREMESO CHE lo SPONSOR ha stipulato un contratto con Parexel International (IRL) Limited o una sua affiliata (di seguito “CRO”) (in base ad un accordo scritto separato) per agire come contraente e incaricato dello SPONSOR nella gestione dello Studio per conto dello SPONSOR, in conformità con il Protocollo; e</p>	<p>WHEREAS, SPONSOR has contracted with Parexel International (IRL) Limited or an Affiliate (hereinafter “CRO”) (under a separate written agreement) to act as SPONSOR’s contractor and designee in managing the Study for SPONSOR, in accordance with the Protocol; and</p>
<p>PREMESSO CHE le Parti hanno stipulato il suddetto Accordo in data 17 Settembre 2024</p>	<p>WHEREAS, the Parties have entered into the above-referred Agreement dated 17 September 2024</p>

PREMESSO CHE il 01 ottobre 2024 l'indirizzo legale dello SPONSOR è cambiato da 3545 Cray Court, San Diego, California, 92121, USA a Route 206 and Province Line Road, Princeton, New Jersey, 08543, USA.	WHEREAS, on 01 Oct 2024, the SPONSOR's legal address changed from 3545 Cray Court, San Diego, California, 92121, USA to Route 206 and Province Line Road, Princeton, New Jersey, 08543, USA.
PREMESSO CHE a seguito dell'emendamento n. 3 del Protocollo del 20 agosto 2024 (di seguito "emendamento del Protocollo"), approvato dal Comitato Etico Territoriale Lombardia 2 nella seduta del 9 aprile 2025 e da Autorizzazione EMA del 26 maggio 2025 le Parti convengono di modificare l'Accordo per includere un budget rivisto in conformità alle modifiche apportate da tale emendamento del Protocollo.	WHEREAS, due to Protocol amendment #3 dated 20 Aug 2024 (hereinafter "Protocol amendment"), approved by the Territorial Ethics Committee of Lombardia 2 in the session of 9 April 2025 and by EMA authorization on 26 May 2025 the Parties agree to amend the Agreement to include revised budget in accordance with the changes in the said Protocol amendment.
PREMESSO CHE che le Parti sono congiuntamente disposte a modificare il suddetto Accordo;	WHEREAS, the Parties are jointly willing to amend the above-referred Agreement;
Il presente Emendamento è da considerarsi efficace a partire dalla data di approvazione dell'Emendamento al Protocollo da parte dell'Autorità competente.	This Amendment shall be considered effective from the date of approval of the Protocol Amendment by the competent Authority.
1. All'art. 6.7 dell'Accordo, per quanto riguarda l'emissione della fattura elettronica, l'indirizzo dello SPONSOR è sostituito come segue: Mirati Therapeutics, Inc. Route 206 and Province Line Road Princeton, New Jersey, 08543, USA Tax ID number: 46-2693615	1. In Art 6.7 of the Agreement with regard to issuing the electronic invoice, the SPONSOR's address shall be replaced as follows: Mirati Therapeutics, Inc. Route 206 and Province Line Road Princeton, New Jersey, 08543, USA Tax ID number: 46-2693615
2. Nella sezione 8 dell'Allegato A e dell'Allegato C dell'Accordo, con riferimento alla Fattura emessa nei confronti dello SPONSOR, l'indirizzo dello SPONSOR sarà sostituito come segue Mirati Therapeutics, Inc. Route 206 and Province Line Road Princeton, New Jersey, 08543, USA Tax ID number: 46-2693615 Email: accountspayable@mirati.com	2. In Section 8 of Annex A and Annex C of the Agreement with regard to the Invoice issued to the SPONSOR, the SPONSOR's address shall be replaced as follows: Mirati Therapeutics, Inc. Route 206 and Province Line Road Princeton, New Jersey, 08543, USA Tax ID number: 46-2693615 Email: accountspayable@mirati.com
3. A causa di una modifica del Protocollo, l'Allegato A - Programma dei Pagamenti e Budget viene eliminato nella sua interezza e sostituito con l'Allegato A - Programma dei Pagamenti e Budget rivisto allegato alla presente	3. Due to a Protocol amendment, Annex A – Payment Schedule and Budget is hereby deleted in its entirety and replaced with the revised Annex A - Payment Schedule and Budget attached hereto,
In caso di conflitto tra i termini del presente Emendamento e l'Accordo, i termini del presente Emendamento prevarranno.	In the event of a conflict between the terms of this Amendment and the Agreement, the terms of this Amendment shall take precedence.
Tutti i termini in maiuscolo utilizzati e definiti nel presente documento avranno il significato attribuito a tali termini nel presente documento e tutti i termini in maiuscolo utilizzati ma non definiti nel presente documento avranno il significato attribuito a tali termini nel Contratto. Tutti gli altri termini e condizioni del suddetto Accordo rimangono invariati e in pieno vigore.	Any capitalized terms used and defined herein shall have the meaning ascribed to such terms herein and any capitalized terms used but not defined herein shall have the meaning ascribed to such terms in the Agreement. All other terms and conditions of the above-referred Agreement remain unchanged and in full force and effect.
IN FEDE DI QUANTO SOPRA , le Parti sottoscrivono il presente Emendamento. Poiché le Parti sottoscrivono il presente Emendamento mediante firma digitale, una volta firmato da tutte	IN WITNESS WHEREOF , the Parties hereby execute this Amendment. As the Parties are signing this Amendment by means of digital signature, once signed by all Parties, they agree

le Parti, queste ultime convengono che il presente atto costituisce l'unico originale informatico, legalmente vincolante.

that this act is the single original electronic document, legally binding.

PER IL PROMOTORE/ ON BEHALF OF THE SPONSOR:

Parexel International (IRL) Limited come rappresentante autorizzato di Mirati Therapeutics/
Parexel International (IRL) Limited as authorized representative of Mirati Therapeutics
Il rappresentante autorizzato/The Authorized Representative

Dott./Dr. Nicola Sotira
Firma/Signature

PER L'ENTE/FOR THE INSTITUTION:

Il Legale Rappresentante o suo delegato / The Legal Representative or its delegate
Il Direttore Amministrativo (per il Direttore Generale Dott. Alberto Carelli)/ The Administrative Director (for General Director Dott. Alberto Carelli)

Dott./Dr Matteo Biraschi
Firma/Signature

Per presa visione delle disposizioni che lo/la riguardano: lo Sperimentatore Principale/For acknowledgment of the provisions that concern him/her: the Principal Investigator

Dr.ssa/Dr. Rita Chiari
Firma/Signature

Visit Schedule	Italy	Sub-Study: All Budgets																						
Cost Per Procedure View		Qty	OH	Budget	SF	SV	C1D1	C1D15	C2D1	C2D15	C3D1	C3D15	C4D1	C4D15	C5D1	C6D1	C7D1	C8D1	EOT	LTFU-M2	LTFU-M4	LTFU-M6	USV	
INCON	Informed Consent	1	✓	43.09																				
INCON	Pre-screening, Genomics consent	1	✓	20.17		20.17																		
81275	Tumor Tissue Genotyping (eligibility) - Tumor Tissue Sample Handling	1	✓	290.62		290.62																		
RANDM	Randomization	1	✓	48.59		48.59																		
T9206	Medical and Disease History, Prior Therapy	1	✓	54.09		54.09																		
36415	Blood draw for - ctDNA	1	✓	12.83		12.83																		
DEMOG	Demographics	1	✓	23.84		23.84																		
50042	ECOG	10	✓	20.17		20.17		20.17		20.17		20.17		20.17		20.17	20.17	20.17	20.17	20.17	20.17	20.17	20.17	20.17
69213	Full Physical Exam	11	✓	80.68		80.68																		
69212	Abbreviated Physical Exam	13	✓	73.34		73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34	73.34
69211	Vital Signs	14	✓	35.75		35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75
65025	Hematology	13	✓	25.67		25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67	25.67
60053	Serum Chemistry	13	✓	47.67		47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67	47.67
63735	Serum Chemistry-Magnesium	13	✓	11.92		11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92	11.92
62150	Amylase	13	✓	23.00		23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00
63690	Lipase	13	✓	16.00		16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00
63000	Single 12-Lead ECG	6	✓	61.42		61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42	61.42
50145	RECIST	5	✓	22.00		22.00		22.00		22.00		22.00		22.00		22.00		22.00		22.00		22.00		22.00
70299	PK Sampling	7	✓	23.84		23.84	47.68	47.68	47.68	47.68	23.84													
50037	PRO Questionnaires - PRO-CTCAE	12	✓	18.34		18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34	18.34
50034	PRO Questionnaires - EQ-5D-5L	9	✓	35.75		35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75	35.75
40617	Adverse Events Including SAE assessments	13	✓	24.75		24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75	24.75
CONMD	Concomitant Medications	14	✓	22.00		22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00
69966	Survival & Anticancer Therapies	4	✓	28.42		28.42															28.42	28.42	28.42	28.42
Procedures Sub Total (€)					€ 0.00	€ 846.68	€ 352.03	€ 298.44	€ 463.46	€ 320.44	€ 439.62	€ 298.44	€ 415.78	€ 320.44	€ 378.20	€ 376.36	€ 378.20	€ 358.02	€ 444.20	€ 28.42	€ 28.42	€ 28.42	€ 0.00	
Code	Non Procedure	Qty	OH	Budget	SF	SV	C1D1	C1D15	C2D1	C2D15	C3D1	C3D15	C4D1	C4D15	C5D1	C6D1	C7D1	C8D1	EOT	LTFU-M2	LTFU-M4	LTFU-M6	USV	
NP021	Study Coordinator, Simple-Data entry	18	✓	56.84		113.68	56.84	56.84	56.84	56.84	56.84	56.84	56.84	56.84	56.84	56.84	56.84	56.84	56.84	56.84	56.84	56.84	56.84	
NP006	Pharmacy, Simple-Adagresib Dispensing (D) & Reconciliation (R)	9	✓	32.09		32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	32.09	
NP023	Study Nurse	15	✓	57.76		115.52	57.76	57.76	57.76	57.76	57.76	57.76	57.76	57.76	57.76	57.76	57.76	57.76	57.76	57.76	57.76	57.76	57.76	
NP025	PI Time	15	✓	112.76		225.52	112.76	112.76	112.76	112.76	112.76	112.76	112.76	112.76	112.76	112.76	112.76	112.76	112.76	112.76	112.76	112.76	112.76	
Non Procedures Sub Total (€)					€ 0.00	€ 454.72	€ 259.45	€ 227.36	€ 259.45	€ 56.84	€ 56.84	€ 56.84	€ 0.00											
Overhead (all costs) (5%)					€ 0.00	€ 247.27	€ 116.18	€ 99.90	€ 137.35	€ 104.08	€ 132.82	€ 99.90	€ 128.29	€ 104.08	€ 121.15	€ 120.80	€ 121.15	€ 117.32	€ 133.69	€ 16.20	€ 16.20	€ 16.20	€ 0.00	
Total Cost Per Visit with Overhead(€)					€ 0.00	€ 1,548.67	€ 727.66	€ 625.70	€ 860.26	€ 651.89	€ 831.89	€ 625.70	€ 803.52	€ 651.88	€ 758.80	€ 756.61	€ 758.80	€ 734.79	€ 837.34	€ 101.46	€ 101.46	€ 101.46	€ 0.00	
Total Cost Per Patient (€)					€ 11,477.88																			
Planned Number of Patients					1																			
Total Cost for All Patients					€ 11,477.88																			

Code	Conditional Procedure	Qty	OH	Budget	RF	SV	C1D1	C1D1S	C2D1	C2D1S	C3D1	C3D1S	C4D1	C4D1S	C5D1	C6D1	C7D1	C8D1	EOT	LTRU-M2	LTRU-M4	LTRU-M6	USV	
INCON	Informed Consent	1	✓	43.09	43.09																			
GNCON	Pre-screening, Genomics consent	1	✓	20.17	20.17																			
17312	Fresh Tumor Biopsy	2	✓	301.62	301.62	301.62																		
81275	Tumor Tissue Genotyping (confirmation/other) - Tumor Tissue Sample Handling (SF, 30 days after first dose and -optional- at disease progression)	3	✓	290.62	290.62	290.62																	290.62	
8480N	Randomization	1	✓	46.59	46.59																			
12306	Medical and Disease History, Prior Therapy	1	✓	54.09	54.09																			
36415	Blood draw for CDNA (At disease progression (optional))	2	✓	12.83	12.83															12.83				
DENOG	Demographics	1	✓	23.84	23.84																			
50942	ECOG	1	✓	20.17	20.17																			
99213	Full Physical Exam	1	✓	80.68	80.68																			
99173	Ophthalmology examination - visual acuity test (if clinically indicated)	2	✓	23.84	23.84	23.84																		
12282	Ophthalmology examination - Slit lamp examination (if clinically indicated)	2	✓	43.09	43.09	43.09																		
92225	Ophthalmology examination - Fundoscopic examination (if clinically indicated)	2	✓	55.92	55.92	55.92																		
99212	Abbreviated Physical Exam	1	✓	73.34	73.34																		73.34	
99211	Vital Signs	2	✓	35.75	35.75																		35.75	
85025	Hematology	3	✓	25.67	25.67	25.67																	25.67	
80053	Serum Chemistry	3	✓	47.67	47.67	47.67																	47.67	
83735	Serum Chemistry-Magnesium	3	✓	11.92	11.92	11.92																	11.92	
82150	Amylase	3	✓	23.00	23.00	23.00																	23.00	
83690	Urease	3	✓	16.00	16.00	16.00																	16.00	
93000	Single 12-Lead ECG (as clinically indicated)	2	✓	61.42	61.42	61.42																		
93307	ECHO	3	✓	279.62	279.62	279.62										279.62								
83307	Interpretation and Report; ECHO	3	✓	117.35	117.35	117.35										117.35								
79872	MUGA	3	✓	520.73	520.73	520.73																		
88472	Interpretation and Report; MUGA	3	✓	97.18	97.18	97.18										97.18								
ADEV7	Adverse Events	1	✓	24.75	24.75																		24.75	
SADEV	Serious adverse events (SAE) - per occurrence	3	✓	67.84	67.84	67.84																	67.84	
CONMD	Concomitant Medications	2	✓	22.00	22.00																		22.00	
10703	HEV, HBV, HCV Serology (in specified countries)	2	✓	54.09	54.09	54.09																		
87517	HEV-DNA	2	✓	88.93	88.93	88.93																		
87902	HCV-RNA	2	✓	218.19	218.19	218.19																		
84702	Serum pregnancy test	12	✓	26.59	26.59	26.59	26.59		26.59		26.59		26.59		26.59	26.59	26.59	26.59		26.59		26.59	26.59	
84703	Urine pregnancy test	12	✓	19.25	19.25	19.25	19.25		19.25		19.25		19.25		19.25	19.25	19.25	19.25		19.25		19.25	19.25	
83001	PSM	2	✓	43.09	43.09	43.09																		
NP023	Study Coordinator, Simple-Data entry	2	✓	56.84	56.84																		56.84	
NP023	Study Nurse	2	✓	57.76	57.76																		57.76	
NP025	PI Time	2	✓	112.76	112.76																		112.76	
70552	MRI Brain with contrast	6	✓	1,025.88	1,025.88	1,025.88				1,025.88				1,025.88		1,025.88		1,025.88						
R0552	Interpretation and Report; MRI Brain with contrast	6	✓	242.95	242.95	242.95				242.95				242.95		242.95		242.95						
70551	MRI - brain without contrast	6	✓	956.20	956.20	956.20				956.20				956.20		956.20		956.20						
R0551	Interpretation and Report; MRI - brain without contrast	6	✓	175.10	175.10	175.10				175.10				175.10		175.10		175.10						
70460	CT Brain with contrast	6	✓	548.23	548.23	548.23				548.23				548.23		548.23		548.23						
R0460	Interpretation and Report; CT Brain with contrast	6	✓	121.93	121.93	121.93				121.93				121.93		121.93		121.93						
70450	CT - brain without contrast	6	✓	506.06	506.06	506.06				506.06				506.06		506.06		506.06						
R0450	Interpretation and Report; CT - brain without contrast	6	✓	112.76	112.76	112.76				112.76				112.76		112.76		112.76						
71260	CT - Chest with contrast	6	✓	617.91	617.91	617.91				617.91				617.91		617.91		617.91						
R1260	Interpretation and Report; CT - Chest with contrast	6	✓	134.77	134.77	134.77				134.77				134.77		134.77		134.77						
71250	CT - Chest without contrast	6	✓	575.74	575.74	575.74				575.74				575.74		575.74		575.74						
R1250	Interpretation and Report; CT - Chest without contrast	6	✓	111.85	111.85	111.85				111.85				111.85		111.85		111.85						
T1010	CT; abdomen and pelvis with contrast	6	✓	849.85	849.85	849.85				849.85				849.85		849.85		849.85						
87010	Interpretation and Report; CT; abdomen and pelvis with contrast	6	✓	161.35	161.35	161.35				161.35				161.35		161.35		161.35						
80145	RECTCT	1	✓	22.00	22.00																			
74178	CT; abdomen and pelvis; without contrast	6	✓	1,116.64	1,116.64	1,116.64				1,116.64				1,116.64		1,116.64		1,116.64						
84178	Interpretation and Report; CT; abdomen and pelvis; without contrast	6	✓	179.69	179.69	179.69				179.69				179.69		179.69		179.69						
71551	MRI; chest with contrast	6	✓	1,053.38	1,053.38	1,053.38				1,053.38				1,053.38		1,053.38		1,053.38						
R1551	Interpretation and Report; MRI; chest with contrast	6	✓	186.11	186.11	186.11				186.11				186.11		186.11		186.11						
71550	MRI; chest without contrast	6	✓	921.36	921.36	921.36				921.36				921.36		921.36		921.36						
R1550	Interpretation and Report; MRI; chest without contrast	6	✓	184.27	184.27	184.27				184.27				184.27		184.27		184.27						
74182	MRI; abdomen with contrast	6	✓	804.93	804.93	804.93				804.93				804.93		804.93		804.93						
R4182	Interpretation and Report; MRI; abdomen with contrast	6	✓	165.94	165.94	165.94				165.94				165.94		165.94		165.94						
74181	MRI - abdomen, without contrast	6	✓	761.84	761.84	761.84				761.84				761.84		761.84		761.84						
R4181	Interpretation and Report; MRI - abdomen, without contrast	6	✓	145.77	145.77	145.77				145.77				145.77		145.77		145.77						
72196	MRI; pelvis - with contrast	6	✓	847.10	847.10	847.10				847.10				847.10		847.10		847.10						
R2196	Interpretation and Report; MRI; pelvis -with contrast	6	✓	187.94	187.94	187.94				187.94				187.94		187.94		187.94						
72195	MRI - pelvis, without contrast	6	✓	790.26	790.26	790.26				790.26				790.26		790.26		790.26						
R2195	Interpretation and Report; MRI - pelvis, without contrast	6	✓	160.44	160.44	160.44				160.44				160.44		160.44		160.44						
78816	Whole body PET/CT scan	4	✓	2,398.29	2,398.29	2,398.29				2,398.29				2,398.29		2,398.29		2,398.29						
R8816	Interpretation and Report; Whole body PET/CT scan	4	✓	332.79	332.79																			

Site costs	Qty	Budget
SC003 Study Start-Up Fee/Site Set-Up Fee	1	1.727,21
SC008 Pharmacy: Set-Up Fee	1	800,35
SC020 Document Storage, Archiving	1	779,2